Analysis of B cell receptors expressed on tumor infiltrating B cells by next generation sequencing

2016 Fiscal Year Final Research Report

• Project/Area Number: 15K14410
• Research Category: Grant-in-Aid for Challenging Exploratory Research
• Allocation Type: Multi-year Fund
• Research Field: Tumor therapeutics
• Research Institution: Juntendo University
• Principal Investigator: TAKEDA KAZUYOSHI 順天堂大学, 医学(系)研究科(研究院), 准教授 (80272821)
• Co-Investigator(Renkei-kenkyūsha): SUZUKI Ryuji 独立行政法人国立病院機構(相模原病院臨床研究センター), 診断・治療研究室, 室長 (70373470)
• Project Period (FY): 2015-04-01 – 2017-03-31
• Keywords: B細胞レセプター / 抗体 / T細胞レセプター / 抗腫瘍抗体 / 腫瘍免疫 / 次世代型シークエンサー

Outline of Final Research Achievements

We have examined B cell receptor (BCR)(antibody) expressed on tumor infiltrating B cells (BCRs) by next generation sequencing (NGS).In the tumors that were effectively rejected by immune therapies, BCR clonality was less. Besides, BCRs were highly oligoclonal when we examined TIBs in the immune therapy-resistant tumors, suggesting specific infiltration of TIBs. We now analyze whether alteration of BCR clonality is causes or results of the difference of therapeutic effects. Moreover, we made antibodies produced by TIBs that clonaly infiltrating in resistant tumors and antibodies produced by TIBs commonly observed in several rejected tumors, and we are now going to define their antigens.

Free Research Field

免疫学